Molecular Partners (Switzerland) Market Value
| MOLN Stock | CHF 3.40 0.08 2.41% |
| Symbol | Molecular |
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
| 04/05/2024 |
| 05/05/2024 |
If you would invest 0.00 in Molecular Partners on April 5, 2024 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 30 days. Molecular Partners is related to or competes with COSMO Pharmaceuticals. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 15.96 | |||
| Value At Risk | (5.06) | |||
| Potential Upside | 5.0 |
Molecular Partners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.56) | |||
| Treynor Ratio | (0.15) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Molecular Partners' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Molecular Partners Backtested Returns
Molecular Partners has Sharpe Ratio of -0.0688, which conveys that the firm had a -0.0688% return per unit of risk over the last 3 months. Molecular Partners exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Molecular Partners' Mean Deviation of 2.45, risk adjusted performance of (0.03), and Standard Deviation of 3.24 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.36, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Molecular Partners will likely underperform. Molecular Partners has an expected return of -0.22%. Please make sure to verify Molecular Partners AG maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.34 |
Poor reverse predictability
Molecular Partners AG has poor reverse predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 5th of April 2024 to 20th of April 2024 and 20th of April 2024 to 5th of May 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of -0.34 indicates that nearly 34.0% of current Molecular Partners price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.34 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Molecular Partners lagged returns against current returns
Autocorrelation, which is Molecular Partners stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Molecular Partners' stock expected returns. We can calculate the autocorrelation of Molecular Partners returns to help us make a trade decision. For example, suppose you find that Molecular Partners has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Molecular Partners regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Molecular Partners stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Molecular Partners stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Molecular Partners stock over time.
Current vs Lagged Prices |
| Timeline |
Molecular Partners Lagged Returns
When evaluating Molecular Partners' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Molecular Partners stock have on its future price. Molecular Partners autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Molecular Partners autocorrelation shows the relationship between Molecular Partners stock current value and its past values and can show if there is a momentum factor associated with investing in Molecular Partners AG.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Molecular Partners Correlation, Molecular Partners Volatility and Molecular Partners Alpha and Beta module to complement your research on Molecular Partners. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Molecular Stock analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world |
Molecular Partners technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.